Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCLC | P48506 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 3/20 | 0.32 |
| ▸ | MMP1 | P03956 | 2/20 | 0.32 |
| ▸ | MMP2 | P08253 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | LAP3 | P28838 | 1/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2990247 | 0.82 | MMP1 (0.34) | GCLCFDPSMMP1MMP2CA12 | |
| SCHEMBL7445871 | 0.81 | MMP1 (0.32) | MMP1MMP2CA12CA1CA2 | |
| SCHEMBL6237312 | 0.79 | GCLC (0.33) | GCLCFDPS | |
| SCHEMBL3889930 | 0.77 | MMP8 (0.37) | MMP8 | |
| SCHEMBL11329696 | 0.76 | GCLC (0.32) | GCLC | |
| Phosphonic Acid SCHEMBL6831106 | 0.73 | — | — | |
| SCHEMBL11340658 | 0.73 | FOLH1 (0.36) | CA2 | |
| SCHEMBL3675754 | 0.69 | POLB (0.36) | FDPSMMP8 | |
| SCHEMBL18486667 | 0.68 | HMGCR (0.32) | FDPSMMP1MMP2CA12CA1 | |
| SCHEMBL2992910 | 0.68 | LAP3 (0.34) | GCLCLAP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 416 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8574757-B2 | Nonaqueous electrolytic solution and nonaqueous electrolyte battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2013-11-05 | — | — | US | claimed |
| US-20120264011-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2012-10-18 | — | — | US | claimed |
| EP-1791905-B1 | MIXTURE, POLYESTER COMPOSITION, FILM AND METHOD FOR PRODUCING THE SAME | LURGI ZIMMER GMBH (DE) | 2008-12-03 | — | — | EP | claimed |
| EP-1791905-A1 | MIXTURE, POLYESTER COMPOSITION, FILM AND METHOD FOR PRODUCING THE SAME | Zimmer AG (DE) | 2007-06-06 | — | — | EP | claimed |
| WO-2006034745-A1 | MIXTURE, POLYESTER COMPOSITION, FILM AND METHOD FOR PRODUCING THE SAME | ZIMMER AG (DE) | 2006-04-06 | — | — | WO | claimed |
| US-5386063-A | Forming a synthetic carotenoids chemical intermediates by reacting triethyl-2-phosphonopropionate with fumarylaldehyde and/or fumarylaldehyde dimethylacetal containing carbon isotope | THE CATHOLIC UNIVERSITY OF AMERICA (US) | 1995-01-31 | — | — | US | claimed |
| EP-0260305-B1 | QUINOLINYL ETHER TETRAZOLE AS AGENT FOR THE TREATMENT OF HYPERSENSITIVE AILMENTS | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1992-12-16 | — | — | EP | claimed |
| US-20260078079-A1 | FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NORBORNANE AND NORBORNENE DERIVATIVES | OSMO LABS PBC (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4619391-A1 | SUBSTITUTED N-PROPYLAMINE FUSED HETEROCYCLIC MESCALINE DERIVATIVES | Enveric Biosciences Canada Inc. (CA) | 2025-09-24 | — | — | EP | disclosed |
| US-12358885-B2 | Substituted n-propylamine fused heterocyclic mescaline derivatives | Enveric Biosciences Canada Inc. (CA) | 2025-07-15 | — | — | US | disclosed |
| US-12285437-B2 | Reversing the undesirable pH-profile of doxorubicin via activation of a disubstituted maleamic acid prodrug at tumor acidity | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2025-04-29 | — | — | US | disclosed |
| US-12227482-B2 | Compounds and compositions for the treatment of cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-02-18 | — | — | US | disclosed |
| WO-2024133859-A1 | MALT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-06-27 | — | — | WO | disclosed |
| US-4542132-A | HYDROXY SUBSTITUTED | PFIZER INC. (US) | 1985-09-17 | — | — | US | disclosed |
| EP-0080154-B1 | N-SUBSTITUTED 2-PYRIDYL INDOLES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR THERAPEUTICAL USE | CIBA-GEIGY AG (CH) | 1985-08-28 | — | — | EP | disclosed |
| EP-0059094-B1 | NOVEL CYCLOHEPTANES | ORTHO PHARMACEUTICAL CORPORATION (US) | 1985-07-31 | — | — | EP | disclosed |
| EP-0135318-A1 | Quinazoline cardiac stimulants | Pfizer Limited (GB) | 1985-03-27 | — | — | EP | disclosed |
| US-4360467-A | Process for preparing 8-oxabicyclo[3.2.1]-octane-1-acetic acids | ORTHO PHARMACEUTICAL CORPORATION (US) | 1982-11-23 | — | — | US | disclosed |
| EP-0059094-A1 | Novel cycloheptanes | ORTHO PHARMACEUTICAL CORPORATION (US) | 1982-09-01 | — | — | EP | disclosed |
| US-4322357-A | Novel cycloheptanes | ORTHO PHARMACEUTICAL CORPORATION (US) | 1982-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12227482-B2 | Compounds and compositions for the treatment of cancer | TP53, HCCS, CFTR | GCLC 266/4885FDPS 130/4885MMP1 416/4885 |
| US-20260078079-A1 | FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NORBORNANE AND NORBORNENE DERIVATIVES | CBR1, CBR3, TAS2R1 | GCLC 2694/4885FDPS 1946/4885MMP1 4797/4885 |
| US-12358885-B2 | Substituted n-propylamine fused heterocyclic mescaline derivatives | HTR5A, CHRM5, DRD2 | GCLC 2549/4885FDPS 1697/4885MMP1 4144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.